Patent intelligence · US
US 11607412
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
Patent details — US 11607412
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 21, 2023
- Expiration
- Mar 16, 2043
- Applicant
- TENAX THERAPEUTICS, INC.
- Claims
- 8
- CPC classes
- A61K, A61K31/216, A61K31/41, A61K31/495
Quick answer
US 11607412 (Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)) is held by TENAX THERAPEUTICS, INC.. Status: granted. Granted Mar 21, 2023. Expires Mar 16, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TENAX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/216, A61K31/41, A61K31/495, A61K31/50, A61K31/502
More from TENAX THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11969424
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11701355
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11213524
Pharmaceutical compositions for subcutaneous administration of levosimendan
granted
Frequently asked questions
What is US patent 11607412?
US 11607412 (Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)) is held by TENAX THERAPEUTICS, INC.. Status: granted. Granted Mar 21, 2023. Expires Mar 16, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11607412?
TENAX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11607412 expire?
Our index shows an expiration date of Mar 16, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.